S1500: A Randomized Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968] Crizotinib [NSC #749005] Savolitinib [NSC #785348] and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
![S1500: A Randomized Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968] Crizotinib [NSC #749005] Savolitinib [NSC #785348] and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)](/media/img/siteimg/21.png)
99 years or below
All
Phase
2
1 Location
Brief description of study
Request for review: CIRB Authorization Agreement, see attached.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: TBD, tbd, tbd
-
Age: 99 years or below
-
Gender: All
Updated on
27 Aug 2018.
Study ID: 825168
Please choose between Voice or SMS based delivery of verification code
or